<DOC>
	<DOC>NCT01941680</DOC>
	<brief_summary>Patients are recruited at diagnosis or at relapse of ATLL-HR in French Caribbean islands and Guyana. They all receive Zidovudine and Pegylated Interferon (ZPI). For patients younger than 65 years old, an allogeneic donor is searching out. Patients included at relapse and with lymphoma clinico-biological subtype also receive chemotherapy (CT). Responses are assessed during ZPI+/-CT and eligible patients (depending on age, comorbidities and response criteria) receive allogeneic transplant. Patient follow-up is planned for 3 years old</brief_summary>
	<brief_title>High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma, Adult T-Cell</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Patient &gt;18 years old and â‰¤ 75 years old, with ATLLHR who signed informed consent. Pregnant or nursing women are not eligible; neither are women of childbearing potential unless using effective contraception as determined by the patient's physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>